EQ
EquilliumDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The constructive case is that March 2026 financing materially reduced near-term solvency pressure and gives EQ504 a funded path into clinic, with management guiding to Phase 1 initiation in mid-2026 and data about six months later [#8-K-2026-03-25] [#10-K-2026-03-25].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Additional capital is needed sooner than expected despite runway guidance into 2029.
Momentum
95
Value
41
Sentiment
2
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.40 · Bull $2.60 · Bear $0.80
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $3.33
Why
Momentum95 · Δ7d -
Value41 · Δ7d +0.1
Sentiment2 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
95
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
2
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 95.4 / Value 41.1 / Sentiment 2.5
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$194.74M
Beta
1.87
Shares Out
60.89M
P/E (TTM) · Derived
-13.9
P/S (TTM)
21.77
P/FCF (TTM) · Derived
-6.00
Rev YoY
-100.0%
EPS YoY
-32280.0%
Gross Margin
-
Op Margin
-554.9%
Net Debt
-$22.58M
Current Ratio
10.85
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology